Back Back
Expert Think Tank on <i>EGFR</i>m NSCLC: Module

CE / CME

Expert Think Tank: Lung Cancer Experts Discuss Current Standard of Care and Ongoing Challenges in the Care of Patients With EGFR-Mutated NSCLC

Pharmacists: 1.25 contact hours (0.125 CEUs)

Nurses: 1.25 Nursing contact hours

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits™

Released: September 30, 2022

Expiration: September 29, 2023

Edward B Garon
Edward B Garon, MD, MS
Xiuning Le
Xiuning Le, MD, PhD
Zofia Piotrowska
Zofia Piotrowska, MD
Mark A. Socinski
Mark A. Socinski, MD
Helena Yu
Helena Yu, MD
CME/CE Information

Activity

Progress
1
Course Completed
Claim Certificate

References

  1. Wu YL, Tsuobi M, He J, et al. Osimertinib in resected EGFR-mutated non-small cell lung cancer. N Engl J Med. 2020;383:1711-1723.
  2. Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25:4691-4700.
  3. US Food and Drug Administration. FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations. fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-adjuvant-therapy-non-small-cell-lung-cancer-egfr-mutations. Accessed September 6, 2022.
  4. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.
  5. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342-2350.
  6. Durvalumab prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2021.
  7. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:1301-1311.
  8. Lisberg A, Cummings A, Goldman JW, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. J Thorac Oncol. 2018;13:1138-1145.
  9. Pisters K, Kris MG, Gaspar LE, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I-IIIA completely resected non-small cell lung cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022;40:1127-1129.
  10. Chen RL, Sun LL, Cao Y, et al. Adjuvant EGFR-TKIs for patients with resected EGFR-mutant non-small cell lung cancer: a meta-analysis of 1,283 patients. Front Oncol. 2021;11:629394.
  11. Atezolizumab prescribing information. South San Francisco, CA: Genentech, Inc.; 2022.
  12. US Food and Drug Administration. FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer. fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer. Accessed September 6, 2022.
  13. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomized, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344-1357.
  14. Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22:4585-4593.
  15. Osimertinib prescribing information. Waltham, MA: AstraZeneca Pharmaceuticals LP; 2022.
  16. Ahn MJ, Cho BC, Ou X, et al. Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: a phase 1b, open-label, multicenter trial. J Thorac Oncol. 2022;17:718-723.
  17. Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol. 2019;30:839-844.
  18. Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-125.
  19. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with simertinib in untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41-50.
  20. Le X, Nilsson M, Goldman J, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol. 2021;16:205.
  21. Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:1655-1669.
  22. US Food and Drug Administration. FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC. fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-plus-erlotinib-first-line-metastatic-nsclc#:~:text=On%20May%2029%2C%202020%2C%20the,exon%2021%20(L858R)%20mutations. Accessed September 6, 2022.
  23. Nishio K, Seto T, Nishio M, et al. Ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated metastatic EGFR-mutated NSCLC: RELAY Japanese subset. JTO Clin Res Rep. 2021;2:100171.
  24. Robichaux JP, Le X, Vijayan RSK, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597:732-737.
  25. Afatinib prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2022.
  26. Yang JCH, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16:830-838.
  27. Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR Mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol. 2020;38:488-495.
  28. Yu HA, Suzawa K, Jordan E, et al. Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR Kinase inhibitors and characterization of MTOR as a mediator of resistance. Clin Cancer Res. 2018;24:3108-3118.
  29. Vokes NI, Chambers E, Nguyen T, et al. Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma. J Thorac Oncol. 2022;17:779-792.
  30. Zhang Y, Zeng L, Zhang X, et al. Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC. BMC Med. 2021;19:245.
  31. Nagasaka M, Zhu VW, Lim SM, et al. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. J Thorac Oncol. 2021;16:740-763.
  32. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240-2247.
  33. Schoenfeld AJ, Chan JM, Kubota D, et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin Cancer Res. 2020;26:2654-2663.
  34. Marcoux N, Gettinger SN, O’Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol. 2019;37:278-285.
  35. Suzawa K, Offin M, Schoenfeld AJ, et al. Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer. JCO Precis Oncol. 2019;3:PO.19.00011.
  36. Tepotinib prescribing information. Rockland, MA: EMD Serono, Inc.; 2021.
  37. Yu HA, Goldberg SB, Le X, et al. Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD.) Clin Lung Cancer. 2021;22:601-606.
  38. Piotrowska Z, Isozaki H, Lennerz JK, et al. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov. 2018;8:1529-1539.
  39. Soria J-C, Wu Y-L, Nakagawa K, et al. Gefitnib plus chemotherapy versus placebo in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomized trial. Lancet Oncol. 2015;16:990-998.
  40. Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8:346-351.
  41. Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37:1558-1565.
  42. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301.
  43. Socinski MA, Nishio M, Jotte RM, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16:1909-1924.
  44. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7:387-401.
  45. Lu S, Wu L, Jian Y, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022;23:1167-1179.
  46. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078-2092.
  47. White MN, Piper-Vallillo AJ, Gardner RM, et al. Chemotherapy plus immunotherapy versus chemotherapy plus bevacizumab versus chemotherapy alone in EGFR-mutant NSCLC after progression on osimertinib. Clin Lung Cancer. 2022;23:e210-e221.
  48. Hosomi Y, Morita S, Sugawara S. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020;38:115-123.
  49. Noronha V, Patil VM, Joshi A. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38:124-136.
  50. Kallergi G, Kontopodis E, Ntzfia A, et al. Effect of osimertinib on CTCs and ctDNA in EGFR mutant non-small cell lung cancer patients: The prognostic relevance of liquid biopsy. Cancers (Basel). 2022;14:1574.
  51. Yu HA, Ambrose H, Baik C. et al. ORCHARD osimertinib + savolitinib interim analysis: a biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract 1239P.
  52. Jänne PA, Baik C, Su W, et al. Efficacy and safety of patritumab deruxtecan (HER3-Dxd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov. 2022;12:74-89.
  53. Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Mol Cancer Ther. 2020;19:2044-2056.
  54. Amivantamab prescribing information. Raritan, NJ: Janssen Biotech, Inc.; 2021.
  55. Ahn M-J, Han J-Y, Lee KH, et al. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Lancet Oncol. 2019;20:1681-1690.
  56. Bauml J, Chul Cho B, Park K, et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naive EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 9006.
  57. Shu CA, Goto K, Ohe Y, et al. Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 9006.
  58. Garon E, Johnson M, Lisberg A, et al. TROPION-PanTumor01: updated results from the NSCLC cohort of the phase 1 study of datopotamab deruxtecan in solid tumors. Presented at: 2021 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 8-14, 2021. Abstract MA03.02.
  59. Mobocertinib PI prescribing information. Lexington, MA: Takeda Pharmaceuticals America, Inc.; 2021.
  60. Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39:3391-3402.
  61. Zhou C, Ramalingam SS, Kim TM, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 2021;7:e214761.
  62. Le X, Cornelissen R, Garassino M, et al. Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 Trial. J Clin Oncol. 2022;40:710-718.
  63. Tsuboi M, Wu Y, Grohe C, et al. Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA. Presented at: 2022 European Society for Medical Oncology Congress; September 9-13, 2021. Abstract LBA47.

BACK | NEXT
Claim Certificate